Clinical Research Directory
Browse clinical research sites, groups, and studies.
Phase 1/2 Study of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
Sponsor: Mahzi Therapeutics
Summary
The goal of this clinical trial is to learn if MZ-1866 is a safe and tolerable treatment for children and adults with Pitt Hopkins Syndrome. To evaluate the safety of MZ-1866, the following will be evaluated: * frequency and severity of adverse events * physical exam, laboratory results and electrocardiogram findings Participants will: * receive a single dose of MZ-1866 by intracerebroventricular injection * be seen by the study physician and site staff periodically to assess changes to their health status * be periodically evaluated using neurodevelopmental tools Caregivers will: * be interviewed periodically about the health status and development of the participant * keep diaries and complete periodic questionnaires regarding participant symptoms
Official title: Phase 1/2 First-in-Human Study to Evaluate the Safety, Tolerability, and Efficacy of MZ-1866, an AAV-9 Gene Therapy Delivered by Intracerebroventricular Injection to Participants With Pitt Hopkins Syndrome
Key Details
Gender
All
Age Range
2 Years - 25 Years
Study Type
INTERVENTIONAL
Enrollment
12
Start Date
2025-12-19
Completion Date
2029-07
Last Updated
2026-02-23
Healthy Volunteers
No
Conditions
Interventions
MZ-1866
AAV-9 gene therapy delivered by intracerebroventricular injection
Locations (3)
UCSF Benioff Children's Hospital Oakland
Oakland, California, United States
Children's Hospital Colorado
Aurora, Colorado, United States
Rush University Medical Center
Chicago, Illinois, United States